SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has successfully concluded its fiscal year 2025. Revenue rose to EUR 986.2 million, representing an increase of 5.8 percent at constant currencies (reported +3.0 percent). Full-year EBITDA grew even stronger and amounted to EUR 280.3 million, up 11.5 percent at constant currencies (reported +8.8 percent). The corresponding EBITDA margin was 28.4 percent (reported 28.4 percent).
“Amid the challenging macroeconomic environment, SCHOTT Pharma once again delivered excellent results, and we met our targets for both revenue and profitability. While our core solutions remain a very solid and profitable business, we have effectively continued to focus on increasing the revenue share of our high-value solutions through product innovation, capacity expansions, and strong partnerships,” said SCHOTT Pharma’s CEO Andreas Reisse. “As we expect the market to remain difficult, we target a revenue growth of 2 to 5 percent for fiscal year 2026 and an EBITDA margin of around 27 percent. This represents a bridge year, as we anticipate market dynamics to pick up again going forward. We update our mid-term guidance and now project a revenue CAGR of 6 to 8 percent and an incremental increase of our EBITDA margin over the coming years.”
Reinhard Mayer, CFO of SCHOTT Pharma, added, “The disciplined execution of our strategy in 2025 has further strengthened SCHOTT Pharma’s financial foundation and bolstered our resilience against the backdrop of geopolitical uncertainties. Over the last six years, we have invested around EUR 800 million in our global manufacturing network, particularly for high-value solutions. At the same time, we have further improved our efficiency through automation and digitisation, which is also reflected in the positive development of our EBITDA margin. Looking ahead, we remain committed to investing in innovation, capacity and operational excellence to drive sustainable, profitable growth alongside our mid-term expectations.”
The full report is available here.